Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy

European Heart Journal

Volumn 29, Issue 7, 2008, Pages 898-906

  García Bolao, Ignacio ^a   López, Begoña ^b   MacÍas, Alfonso ^a   Gavira, Juan J ^a   Azcárate, Pedro ^a   Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Collagen; Heart failure; Resynchronization

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1;

AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARDIAC RESYNCHRONIZATION THERAPY; COLLAGEN SYNTHESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; LONG TERM CARE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; CARDIAC PACING, ARTIFICIAL; COLLAGEN TYPE I; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WALKING;

EID: 41849137218     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn098     Document Type: Article

References (32)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ, Task Force for the Diagnosis Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
2. Duncan A, Wait D, Gibson D, Daubert JC, MUSTIC (Multisite Stimulationin Cardiomyopathies) Trial. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC (Multisite Stimulationin Cardiomyopathies) trial. Eur Heart J 2003;24:430-441.
3. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White GB, DeVries DW, Feldman AM, Comparison of Medical Therapy, Pacing, Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) Investigators. N Engl J Med 2004;350:2140-2150.
4. Diaz-Infante E, Mont L, Leal J, Garcia-Bolao I, Fernandez-Lozano I, Hernandez-Madrid A, Pérez-Castellano N, Sitges M, Pavón- Jiménez R, Barba J, Cavero MA, Moya JL, Pérez-Isla L, Brugada J, SCARS Investigators. Predictors of lack of response to resynchronization therapy. Am J Cardiol 2005;95:1436-1440.
5. Kass DA. Ventricular dyssynchrony and mechanisms of resynchronization therapy. Eur Heart J Suppl. 2002;4(Suppl. D):D23-D30.
6. Donal E, Leclercq C, Linde C, Daubert JC. Effects of cardiac resynchronization therapy on disease progression in chronic heart failure. Eur Heart J 2006;27:1018-1025.
7. Vernooy K, Verbeek XA, Peschar M, Crijns HJ, Arts T, Cornelussen RN, Prinzen FW. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J 2005;26:91-98.
8. Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, Girardot R, Crepin D, Reant P, Roudaut R, Jaïs P, Haissaguerre M, Clementy J, Jimenez M. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004;110:3766-3772.
9. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effect of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035.
10. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 2004;110:1263-1268.
11. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990;3:735-740.
12. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993;88:993- 1003.
13. D'Ascia C, Cittadini A, Monti MG, Riccio G, Sacca L. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium. Eur Heart J 2006;27:201-206.
14. García-Bolao I, Macías A, López B, Gonzákez A, Gavira JJ, Azcárate P, Alegría E, Díez J. A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. J Am Coll Cardiol 2006;47:2335-2337.
15. Weber KT, Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991;12:61-69.
16. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Mindán JP. Serum markers of collagen type I metabolism in spontaneously hypertensive rats. Relation to myocardial fibrosis. Circulation 1996;93:1026-1032.
17. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
18. ATS. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
19. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005;26:778-793.
20. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
21. Janousek J, Tomek V, Chaloupecky VA, Reich O, Gebauer RA, Kautzner J, Hucin B. Cardiac resynchronization therapy: a novel adjunct to the treatment and prevention of systemic right ventricular failure. J Am Coll Cardiol 2004;44:1927-1931.
22. Popovic ZB, Grimm RA, Perlic G, Chincov E, Geraci M, Sun JP, Donal E, Xu XF, Greenberg NL, Wilkoff BL, Thomas JD. Noninvasive assessment of cardiac resynchronization therapy for congestive heart failure using myocardial strain and left ventricular peak power as parameters of myocardial synchrony and function. J Cardiovasc Electrophysiol 2002;13:1203-1208.
23. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540.
24. Nimmi ME. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. In: Zern MA, Reid LM, eds, Extracellular Matrix. New York: Marcel Decker; 1993. p121-148.
25. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000;46:257-263.
26. Atance J, Yost MJ, Carver W. Influence of the extracellular matrix on the regulation of cardiac fibroblast behaviour by mechanical stretch. J Cell Physiol 2004;200:377-386.
27. Díez J. Mechanisms of cardiac fibrosis. J Clin Hypertens 2007;9:546-550.
28. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M, Francolini G, Dienberger I, Bacchi L, Rapezzi C, Ferrari R, Branzi A. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 2006;27:1776-1786.
29. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987;252:C1-C9.
30. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
31. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
32. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006;69:666-676.